Literature DB >> 6690090

Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts.

C Zlotogorski, L C Erickson.   

Abstract

We have recently shown that a variety of human tumor cell lines are capable of preventing chloroethylnitrosourea (CNU)-induced DNA crosslinks, presumably by removing guanine O6-chloroethyl DNA monoadducts before crosslinks can form. Those cells capable of preventing crosslinking were of the Mer+ (Methylation repair) phenotype, and have been shown to be proficient at repair of O6-methyl-guanine adducts by the repair enzyme guanine-O6-methyl-transferase. Mer- tumor cell lines are: deficient at O6-methyl-guanine repair, incapable of preventing CNU interstrand crosslinking, and have recently been shown to lack the repair enzyme O6-methyl-transferase. We wish to report that pretreatment of Mer+ cells (HT-29 human colon carcinoma cells and IMR-90 normal human fibroblasts) with the DNA methylating agent MNNG, under conditions which should inactivate O6-methyl-transferase, apparently saturates the monoadduct repair system, and allows CNU to form interstrand crosslinks in these cells. This effect was also seen when MNU pretreatment was used, but not with MMS or streptozotocin. The formation of CNU-induced interstrand crosslinks following MNNG or MNU pretreatment was coincident with a dramatic increase in cytotoxicity as measured by colony formation assays. In contrast, cytotoxicity was only slightly increased when MMS or streptozotocin pretreatment was used.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690090     DOI: 10.1093/carcin/5.1.83

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

Review 1.  Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Authors:  Bernd Kaina; Geoffrey P Margison; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

2.  Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.

Authors:  M E Dolan; G L Larkin; H F English; A E Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene.

Authors:  J Brennand; G P Margison
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Possible depletion of a DNA repair enzyme in human lymphoma cells by subversive repair.

Authors:  P Karran
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

6.  6-Methylguanine and 6-methylguanosine inhibit colony-forming ability in a malignant xeroderma pigmentosum cell line but not in other xeroderma pigmentosum and normal human fibroblast strains after treatment with 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea.

Authors:  H W Thielmann; L Edler; N Müller; G Eisenbrand
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

7.  O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.

Authors:  T P Brent; P J Houghton; J A Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

8.  In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.

Authors:  S M Lee; N Thatcher; D Crowther; G P Margison
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

Authors:  S M Lee; N Thatcher; D Crowther; G P Margison
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

10.  Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

Authors:  S M Lee; N Thatcher; M Dougal; G P Margison
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.